ApiJect Holdings, Inc., the parent company of ApiJect Systems, Corp., a medical technology public-benefit corporation transforming the fill and finish and delivery of injectable vaccines and medicines, announced that it had completed a US$111 million private round of investment. The new round was led by Royalty Pharma and Jefferies Financial Group (NYSE: JEF), which acquired a revenue interest in addition to equity.
Latham & Watkins LLP represents ApiJect Holdings, Inc. in the investment round with a corporate team led by New York partner Nathan Ajiashvili and Boston partner Daniel Hoffman, with Chicago associates Jana Kovich, Kristine LaVeau, and Autumn Schmidt. Advice was also provided on benefits & compensation matters by Washington, D.C. partner David Della Rocca and Chicago associate Victoria Wolfe; on tax matters by New York partner Eric Kamerman; on antitrust matters by Washington, D.C. counsel Joseph Simei; and on CFIUS matters by Washington, D.C. partner Jim Barker.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.